Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
NEW YORK, June 08, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired common stock of Avinger, Inc. (“Avinger”) (NASDAQ:AVGR) pursuant and/or traceable to the Company’s Stock Offering on or about January 30, 2015. To get more information go to:
http://www.zlk.com/pslra/avinger-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that the Registration Statement and Prospectus filed for the Company’s Initial Public Offering contained materially false and misleading statements and/or failed to disclose that: (1) Avinger did not have adequate sales and marketing personnel to increase sales of its lumivascular platform products and to commercialize Pantheris; (2) the Company already experienced problems with the robustness of its lumivascular platform devices, including Pantheris; (3) physicians and hospitals were requiring more extensive and comprehensive training and education on the benefits of Avinger’s products to convince them to adopt and implement its lumivascular platform products compared to competing products and procedures available in the market; (4) Avinger would not be able to achieve a rapid ramp rate for increased sales of its lumivascular platform; and (5) as a result, the Company was experiencing lower sales and revenues.
Avinger priced its IPO at $13 per share. Since the IPO, however, Avinger stock has fallen to a recent close of $0.36 per share on May 23, 2017.
If you suffered a loss in Avinger and would like to obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/avinger-inc.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
